Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600351 | 1.00 | MAPK1 (0.37) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL29900348 | 0.91 | BRD4 (0.40) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL21101078 | 0.91 | BRD4 (0.40) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL21074853 | 0.91 | BRD4 (0.40) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL30853499 | 0.91 | BRD4 (0.40) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL22488629 | 0.91 | BRD4 (0.40) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL22138895 | 0.89 | BRD4 (0.39) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL29438321 | 0.89 | BRD4 (0.39) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL22120512 | 0.89 | BRD4 (0.39) | MAPK1BRD4CREBBPTRPV1P2RX7 | |
| SCHEMBL20600363 | 0.89 | MAPK1 (0.40) | MAPK1BRD4CREBBPTRPV1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064160-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (US) | 2022-03-03 | — | — | US | claimed |
| CN-110770227-B | Novel azaquinoline derivatives | 拜耳动物保健有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20220064160-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064160-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, PIGS | MAPK1 3920/4885BRD4 125/4885CREBBP 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.